PE20240809A1 - Composiciones y metodos de los anticuerpos anti-pacap - Google Patents
Composiciones y metodos de los anticuerpos anti-pacapInfo
- Publication number
- PE20240809A1 PE20240809A1 PE2024000157A PE2024000157A PE20240809A1 PE 20240809 A1 PE20240809 A1 PE 20240809A1 PE 2024000157 A PE2024000157 A PE 2024000157A PE 2024000157 A PE2024000157 A PE 2024000157A PE 20240809 A1 PE20240809 A1 PE 20240809A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- cdr1
- seq
- present
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgacion refiere a anticuerpos humanizados anti-PACAP, que comprenden secuencias de la region variable de la cadena pesada (VH)-CDR1, VH-CDR2 y VH-CDR3 establecidas en SEQ ID NO: 9, 2 y 3; y de la region variable de la cadena ligera (VL)-CDR1, VLCDR2 y VL-CDR3 establecidas en SEQ ID NO: 10, 5 y 6. Dichas regiones derivan del gen humano IGHV1-69 01 e IGKV4-1 01, respectivamente. Ademas, los presentes anticuerpos comprenden una region constante IgG1 o IgG4. Tambien, la presente refiere a una composicion farmaceutica que comprende un anticuerpo y un portador farmaceuticamente aceptable; un metodo para producir los anticuerpos, en el cual se cultiva una celula modificada con un vector que lo codifica; y el uso de dichos anticuerpos en el tratamiento o prevencion de afecciones como la migrana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226875P | 2021-07-29 | 2021-07-29 | |
| PCT/US2022/074238 WO2023010065A2 (en) | 2021-07-29 | 2022-07-28 | Compositions and methods for anti-pacap antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240809A1 true PE20240809A1 (es) | 2024-04-18 |
Family
ID=85088265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000157A PE20240809A1 (es) | 2021-07-29 | 2022-07-28 | Composiciones y metodos de los anticuerpos anti-pacap |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12358980B2 (es) |
| EP (1) | EP4377343A4 (es) |
| JP (1) | JP2024527029A (es) |
| KR (1) | KR20240046192A (es) |
| CN (1) | CN118556079A (es) |
| AR (1) | AR126603A1 (es) |
| AU (1) | AU2022317808A1 (es) |
| CA (1) | CA3227549A1 (es) |
| CL (1) | CL2024000248A1 (es) |
| CO (1) | CO2024000763A2 (es) |
| IL (1) | IL310329A (es) |
| MX (1) | MX2024001304A (es) |
| PE (1) | PE20240809A1 (es) |
| TW (1) | TW202317643A (es) |
| WO (1) | WO2023010065A2 (es) |
| ZA (1) | ZA202401405B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4377343A4 (en) | 2021-07-29 | 2025-06-18 | Cephalon LLC | COMPOSITIONS AND METHODS FOR ANTI-PACAP ANTIBODIES |
| EP4658683A1 (en) * | 2023-02-01 | 2025-12-10 | Cephalon LLC | Compositions and methods for anti-pacap igg4 antibodies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014786A1 (en) | 1990-03-17 | 1991-10-03 | Takeda Chemical Industries, Ltd. | Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap |
| WO2004062684A2 (en) | 2003-01-16 | 2004-07-29 | D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven | Treatment of thrombocytopenia with inhibitors of pacap |
| EP2048162A4 (en) | 2006-08-08 | 2010-12-01 | Univ Kyoto | NOVEL MONOCLONAL ANTIBODY AND USE THEREOF |
| CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| WO2012106407A2 (en) | 2011-02-01 | 2012-08-09 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
| EP2958943B1 (en) | 2013-02-20 | 2019-09-11 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| CN105143267B (zh) | 2013-03-15 | 2020-06-26 | 美国安进公司 | 人pac1抗体 |
| AU2015318008B2 (en) | 2014-09-15 | 2021-05-20 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
| WO2016168757A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| EP3390447A1 (en) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Pacap antibodies and uses thereof |
| JP7116685B2 (ja) | 2016-04-15 | 2022-08-10 | エイチ． ルンドベック アー／エス | ヒト化抗ｐａｃａｐ抗体及びそれらの使用 |
| WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
| AR113022A1 (es) | 2017-09-29 | 2020-01-15 | Lilly Co Eli | Anticuerpo anti-pacap |
| EP3737699A1 (en) | 2018-01-12 | 2020-11-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
| AU2020304671A1 (en) | 2019-06-28 | 2022-01-20 | Amgen Inc. | Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins |
| EP4377343A4 (en) | 2021-07-29 | 2025-06-18 | Cephalon LLC | COMPOSITIONS AND METHODS FOR ANTI-PACAP ANTIBODIES |
| IL322653A (en) | 2023-02-14 | 2025-10-01 | H Lundbeck As | Treating pain caused by opioids |
| WO2024218541A1 (en) | 2023-04-20 | 2024-10-24 | Mark Hasleton | Treatment of migraine |
-
2022
- 2022-07-28 EP EP22850508.7A patent/EP4377343A4/en active Pending
- 2022-07-28 US US17/815,749 patent/US12358980B2/en active Active
- 2022-07-28 MX MX2024001304A patent/MX2024001304A/es unknown
- 2022-07-28 CN CN202280063638.2A patent/CN118556079A/zh active Pending
- 2022-07-28 KR KR1020247006427A patent/KR20240046192A/ko active Pending
- 2022-07-28 AU AU2022317808A patent/AU2022317808A1/en active Pending
- 2022-07-28 CA CA3227549A patent/CA3227549A1/en active Pending
- 2022-07-28 TW TW111128326A patent/TW202317643A/zh unknown
- 2022-07-28 PE PE2024000157A patent/PE20240809A1/es unknown
- 2022-07-28 AR ARP220102018A patent/AR126603A1/es unknown
- 2022-07-28 JP JP2024504838A patent/JP2024527029A/ja active Pending
- 2022-07-28 IL IL310329A patent/IL310329A/en unknown
- 2022-07-28 WO PCT/US2022/074238 patent/WO2023010065A2/en not_active Ceased
-
2024
- 2024-01-26 CO CONC2024/0000763A patent/CO2024000763A2/es unknown
- 2024-01-26 CL CL2024000248A patent/CL2024000248A1/es unknown
- 2024-02-15 ZA ZA2024/01405A patent/ZA202401405B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12358980B2 (en) | 2025-07-15 |
| US20230212281A1 (en) | 2023-07-06 |
| JP2024527029A (ja) | 2024-07-19 |
| CL2024000248A1 (es) | 2024-08-30 |
| ZA202401405B (en) | 2025-06-25 |
| CN118556079A (zh) | 2024-08-27 |
| CA3227549A1 (en) | 2023-02-02 |
| EP4377343A4 (en) | 2025-06-18 |
| EP4377343A2 (en) | 2024-06-05 |
| IL310329A (en) | 2024-03-01 |
| AR126603A1 (es) | 2023-10-25 |
| AU2022317808A1 (en) | 2024-02-08 |
| WO2023010065A3 (en) | 2023-03-16 |
| WO2023010065A2 (en) | 2023-02-02 |
| CO2024000763A2 (es) | 2024-04-18 |
| MX2024001304A (es) | 2024-05-23 |
| TW202317643A (zh) | 2023-05-01 |
| KR20240046192A (ko) | 2024-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240076375A1 (en) | Anti-TIM-3 Antibodies and Use Thereof | |
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| AR123083A1 (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos | |
| PE20220392A1 (es) | Moleculas de union a claudina-6 y usos de las mismas | |
| PE20240809A1 (es) | Composiciones y metodos de los anticuerpos anti-pacap | |
| PE20231105A1 (es) | Moleculas de union a antigeno multi-especificas contra el vih y metodos de uso | |
| PE20211742A1 (es) | Anticuerpos agonistas de cd200r y sus usos | |
| AR126838A1 (es) | Métodos para preparar células que expresan receptores de antígeno quiméricos | |
| HRP20220197T1 (hr) | Antitijela protiv il-22r | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| PE20230682A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| AR126112A1 (es) | Moléculas de unión a gpc3 | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| KR20240157746A (ko) | Epcam 및/또는 cd137에 결합하는 결합제 | |
| AR099909A1 (es) | Anticuerpos anti-ox40 y métodos de uso | |
| AR124266A1 (es) | Anticuerpos y métodos para el tratamiento de infección por gripe a | |
| CA3213956A1 (en) | Enhanced anti-hvem antibodies and use thereof | |
| AR124721A1 (es) | Anticuerpos contra la calicreína plasmática y usos de estos |